Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Progressive Metastatic Malignancies
Interventions
BIOLOGICAL

ALT-801

Dose escalation (0.015 mg/kg, 0.04 mg/kg, 0.08 mg/kg, 0.12 mg/kg, 0.14 mg/kg, 0.16 mg/kg), intravenous infusions, two treatment cycle, each cycle with 4 daily on-dose infusion, 10 days rest between cycles.

Trial Locations (4)

32806

MD Anderson Cancer Center Orlando, Orlando

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

80045

University of Colorado, Anschutz Cancer Pavillion, Aurora

98109

University of Washington, Seattle Cancer Care Center, Seattle

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Altor BioScience

INDUSTRY

NCT00496860 - Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies | Biotech Hunter | Biotech Hunter